### Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 4

INOVIO PH Form 4 March 07, 20	ARMACEUTICA	ALS, INC.				- ,				
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								PPROVAL 3235-0287		
subject toSTATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF Section 16.Estimated average burden hours per								2005 average Irs per		
(Print or Type I	Responses)									
1. Name and A KIES PETE	Symbol INOVI	2. Issuer Name <b>and</b> Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [INO]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) C/O INOVI PHARMAC INC., 10480	(Month/I 03/05/2	3. Date of Earliest Transaction (Month/Day/Year) 03/05/2017				Director 10% Owner Officer (give title Other (specify below) CFO				
Filed(Mo			endment, Date Original nth/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>			
SAN DIEGO, CA 92121 Person										
(City)							quired, Disposed o		•	
1.Title of Security (Instr. 3)		<ul> <li>2A. Deemed</li> <li>Execution Date, if</li> <li>any</li> <li>(Month/Day/Year)</li> </ul>	Transactie Code (Instr. 8)	on(A) or D (D)	(A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	03/05/2017		M	8,333	A A	<u>(1)</u>	34,859	D		
Common Stock	03/06/2017		F	3,640	D	\$ 6.95	31,219	D		
Common Stock							4,500	I	By Spouse	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)

#### Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 4

# required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	Transaction of Derivative Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Stock Unit	(1)	03/05/2017		М	8,333	<u>(1)</u>	(1)	Common Stock	8,333	ſ

## **Reporting Owners**

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
KIES PETER C/O INOVIO PHARMACEUTICALS, INC. 10480 WATERIDGE CIRCLE SAN DIEGO, CA 92121			CFO	
Signaturaa				

# **Signatures**

Peter Kies 03/07/2017 <u>\*\*</u>Signature of Date Reporting Person

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 25,000
- (1) restricted stock units is as follows: 8,334 shares vested on March 5, 2016; 8,333 shares vested on March 5, 2017; 8,333 shares will vest on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.